Trial Profile
A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination in Women With ER-positive, HER2-negative Advanced Breast Cancer (SERENA-1)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Abemaciclib (Primary) ; Anastrozole (Primary) ; Camizestrant (Primary) ; Capivasertib (Primary) ; Everolimus (Primary) ; Palbociclib (Primary) ; Ribociclib (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer
- Focus Adverse reactions; First in man
- Acronyms SERENA-1
- Sponsors AstraZeneca
- 04 Mar 2024 Planned End Date changed from 12 Sep 2024 to 30 Sep 2024.
- 04 Mar 2024 Planned primary completion date changed from 26 Aug 2024 to 10 Jul 2024.
- 04 Mar 2024 Status changed from recruiting to active, no longer recruiting.